Literature DB >> 8739351

Potential therapeutic indications for synthetic desmuramyl MDP analogue (LK-409).

V Kotnik1, A Stalc.   

Abstract

Synthetic desmuramyl analogues are potentially immunostimulating drugs. Until today a lot of different molecules were constructed, some with interesting augmenting properties, but most of them with unpleasant pyrogenic side effects. LK-409, 7-oxooctanoyl-L-alanyl-D-isoglutamine, synthesised at the Pharmaceutical faculty of Ljubljana, is an apyrogenic derivative with promising immunostimulating activity. LK-409 and the control substance romurtide were tested for more than 50 parameters. All the immune response levels were included in the study; the development and proliferation of stem cells from bone marrow, the natural defence mechanisms with special regard to the function of phagocytic cells, the humoral immune response with special regard to the development of plaque forming cells and the cellular immune response with regard to the proliferating ability of the immune cells and production of regulating and differentiating cytokines, in vitro and in vivo. Results of LK-409 and romurtide activity were sorted in six groups, and evaluated. The analysis shows that LK-409 affects the measured parameters more efficiently than does romurtide. The most pronounced effect was stimulation of the immune response in drug and tumor induced immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8739351     DOI: 10.1007/bf02346355

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  2 in total

Review 1.  Adjuvants: current status, clinical perspectives and future prospects.

Authors:  F M Audibert; L D Lise
Journal:  Immunol Today       Date:  1993-06

2.  Apyrogenic synthetic desmuramyldipeptide, LK-409, with immunomodulatory properties.

Authors:  M Sollner; V Kotnik; S Pecar; A Stace; S Simcic; L Povsic; B Herzog-Wraber; L Klampfer; A Ihan; P Grosman
Journal:  Agents Actions       Date:  1993-03
  2 in total
  1 in total

Review 1.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.